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LETTERS TO THE EDITOR
Regarding “Randomized comparison of percutaneous
Viabahn stent grafts vs prosthetic femoral-popliteal
bypass in the treatment of superficial femoral arterial
occlusive disease”
Until recently, very few randomized studies have been per-
formed on nonpharmacologic treatment of vascular patients.
Therefore, the study by Kedora et al (J Vasc Surg 2007;45:10-16)
comparing two interventional methods is more than welcome. The
authors are to be congratulated for at least two reasons. One is that
they performed a randomized study of this type, which is difficult,
and the other illustrates the huge gap in study outline compared
with randomized study on pharmacologic therapy. It is also wel-
come because it points to the need for properly designed studies on
nonpharmacologic treatment. I have a few questions and com-
ments for the authors:
1. The population of above knee reconstructions points to a rather
benign problem of below groin disease, and there is no defini-
tion of lifestyle-altering claudication. Is it ethical to use a
synthetic material in this situation?
2. Randomization was made by limb, but the limbs are not inde-
pendent in one patient. Although not many bilateral recon-
structions were done, this principle could skew the results.
3. No information is given on sample size calculation.
4. No information is given on whether the study was designed as
a superiority or noninferiority trial, which also would influence
the sample size.
5. The choice of bypass material was left to the discretion of the
surgeon (polytetrafluoroethylene [PTFE] or polyester). Would
it not have been more optimal to use the same material as in the
stent graft (PTFE)?
6. The use of postoperative antiplatelet therapy was not standard-
ized, meaning that 52% of the patients in the bypass group were
given clopidogrel vs 90% in the stent graft group. This could be
an advantage for the stent graft group.
7. There is no definition of 50% stenosis. How was that measured?
8. We have no information if outcome assessment was made in a
blinded manner.
I believe that answers to the above questions would help
readers in how to interpret the results of the study.
David Bergqvist, MD, PhD, FRCS
Professor of Vascular Surgery
Department of Surgical Sciences, Section of Surgery
Uppsala University Hospital
Uppsala, Sweden
doi:10.1016/j.jvs.2007.02.074
Reply
The comments by Dr Bergqvist are welcome and offer addi-
tional insight to our study. The study was designed to evaluate all
patients with superficial femoral arterial occlusive disease that were
to be considered for revascularization. All patients with lifestyle-
limiting claudication had failed attempts at conservative treatment
alone. Although the study cohort included patients with claudica-
tion, as Dr Bergqvist states, it also included those patients with rest
pain and tissue loss. These patient-specific data are outlined by
Rutherford’s clinical classification for ischemia in tabular form in
the article.
We certainly do not argue that venous conduit is still consid-
ered the gold standard for vascular reconstruction in the lower
extremities. Our study, however, was not designed to compare
autologous conduit with synthetic material but, rather, to compare
a percutaneous treatment option with open surgical revasculariza-
tion using synthetic material in both treatment arms. Synthetic
material has been studied and used in the reconstruction of super-
ficial femoral arterial disease for a number of years by many
surgeons as evidenced by numerous publications, including a more
recent meta-analysis of4000 limbs by Dorrucci1 and in a second
report by Bates et al.2 The ethical consideration for any procedure
must be assessed by each physician based on his or her own skill
level and comfort level with the procedure to be considered. Each
patient’s symptoms must also be assessed individually before de-
ciding to proceed with any intervention, and these two treatment
options are certainly no different.
Randomization by limb was performed in all cases, and both
limbs were randomized in 14 patients. There was no statistical
difference in the patient demographic information, as is outlined in
our paper. Because there are no differences in the demographic
stratification and the limbs were prospectively randomized, the
results should not be skewed by the subset of patients with bilateral
randomization.
The study was intended as a noninferiority design, and 50
limbs in each group (100 limbs total) result in a margin of 24% if
we use   0.05 and power  80%. The expanded polytetrafluo-
roethylene (ePTFE)–covered stent graft is considered noninferior
to femoropopliteal surgical bypass if the true patency rate remains
24% of open surgical bypass. This outcome is, in fact, supported
in our study’s primary patency rate of 73% at 1 year for ePTFE
covered stent grafts and 79% at 1 year for surgical femoropopliteal
bypass.
The sample size was calculated before enrollment, allowing for
adequate patient numbers to result in a study powered for a
noninferiority trial. We felt that if we could demonstrate the
outcome between the two treatment arms was equivalent, the
advantage would be gained/realized in the percutaneous arm by a
faster recovery and return to active life with a shorter hospital stay
and less periprocedural pain.
Dacron and ePTFE grafts were allowed for use as a synthetic
conduit at the discretion of the operating surgeon. The goal was to
compare synthetic conduit of the most common types being used
in current everyday practice with the ePTFE-covered stent graft.
We felt that limiting the choice would have only diminished the
value of the study. To our knowledge, no large study has demon-
strated a clear statistically significant difference in the use of ePTFE
vs Dacron for arterial bypass conduit above the knee.
Postoperative clopidogrel was used in 37 (93%) of the 40
patients in the stent graft group. Two patients refused the medi-
cation but did take aspirin, and one patient claimed an allergy to
clopidogrel. In the surgical arm, 24 (52%) of 46 patients were
treated with clopidogrel. Five patients were taking warfarin preop-
eratively, and they were continued on this postoperatively. Seven-
teen patients were treated with aspirin only at the recommendation
of the treating physician. Although this discrepancy could be seen
as an advantage for the stent graft group, there was no statistical
difference between the surgical patients treated with clopidogrel
and those that were not. In addition, our surgical arm patency data
is comparable with historical studies; therefore, we believe there is
no indication of any advantage for either group.1-5 Additional
studies specifically designed to evaluate any advantage the use of
clopidogrel might offer in these two study arms would be helpful
and are being considered at our own institution.
Follow-up was performed by each individual treating physi-
cian; therefore, outcome assessment was not blinded. Follow-up
176
